前收市價 | 34.83 |
開市 | 40.17 |
買盤 | 36.00 |
賣出價 | 45.00 |
拍板 | 940.00 |
到期日 | 2024-05-31 |
今日波幅 | 40.17 - 40.17 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 1 |
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
We’ve recently covered a list of 20 Biggest Publicly-Traded Biotech Companies based on market caps that you can visit here. Biotechnology and Industry 2023: Market Growth, Transformations, and Technological Milestones The global biotechnology market was valued at approximately $1.55 trillion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030, reaching a staggering $3.88 trillion by 2030. The […]